常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.69/-0.39
|
|
企业价值
1.51B
|
| 资产负债 |
|
每股账面净值
0.40
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
314.00K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 02:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. |

4 
